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Subanesthetic IV ketamine reduces acute suicidal ideation in patients with 
mood disorders 
Kimberly J. Jenko, MS, PA-S, Jack Anzilotti, PA-S, Abby Massey, MD. 
James Madison University Physician Assistant Studies, Harrisonburg, Virginia 
 
 
 
ABSTRACT 
 
Background. Depression and suicide are common in the United States and present a significant 
problem in the healthcare landscape. Currently, there are few options that can rapidly reduce 
suicidal ideation in patients with depression. Ketamine, a glutamate N-methyl-D-aspartate 
(NMDA) receptor antagonist, has been shown to reduce acute suicidality in patients with 
depression. Previous studies have a reduction of suicidal ideation compared to saline placebo, 
but few studies have shown a significant effect compared to a similar psychoactive drug such as 
midazolam. 
Method. A search of PubMed and PsychNET was performed in September 2018 using the terms 
“ketamine,” “suicide,” and “depression” with a filter for human clinical trials. Three randomized 
controlled trials were discovered that compared the effects of intravenous (IV) ketamine or 
midazolam on active, acute suicidal ideation in patients with a history of depression. Suicidal 
ideation and depression were measured using similar scales to allow for relative comparison 
between studies. Baseline measurements of suicidal ideation were assessed before IV 
administration of the randomized medications, and repeat assessments were obtained 24 hours 
after administration of the medication.  
Results. All three studies evaluated showed a reduction in suicidal ideation in patients that 
received ketamine compared to those that received midazolam. Grunebaum et al. and Price et al. 
both saw statistically significant reductions in SI in patients who received ketamine and assessed 
with the Beck Scale for Suicidal Ideation (BSI) or the Scale for Suicidal Ideation (SSI). 
Murrough et al. observed a nonsignificant reduction in SI at 24 hours using the BSI, but did see a 
statistically significant reduction using the Montgomery-Asberg Depression Rating Scale 
(MADRS-SI). SI was reduced in the midazolam group in all studies, but none were significant, 
and none as extensive as the ketamine groups.  
Conclusion. Ketamine administered at subanesthetic doses can provide acute relief of suicidal 
ideation in patients with depression within 24 hours. 
 
 
INTRODUCTION 
 
Few options exist to rapidly relieve suicidal ideation in patients with mental health disorders. 
The 2015 National Ambulatory and Medical Care Survey from 2015 indicated that 
approximately 10% of physician office visits are due to depression and as of 2016, suicide is the 
10th leading cause of death in the United States, accounting for approximately 45,000 deaths per 
year.1,2 Behavioral health disorders including bipolar disorder, borderline personality disorder 
(BPD), and particularly major depressive disorder (MDD) are strongly associated with SI. Early 
intervention in depressed individuals using antidepressants is important to reduce the likelihood 
of suicidality. However, current treatment options for acute suicide (hospitalization, medications, 
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psychotherapy and electroconvulsive therapy are not ideal due to the prolonged delay of onset, 
lack of anti-suicidal properties, or significant adverse side effects.3 Some medications, such as 
selective serotonin reuptake inhibitors (SSRIs), have been shown to potentially increase the risk 
of self-harm within weeks of initial administration, and lithium has beneficial effects that can 
takes weeks to manifest.4–6 The initial treatment of acute suicidality for hospitalized patients 
primarily involves protecting them by removing dangerous objects from their room with constant 
monitoring by a trained staff member. Therefore, a pharmacological treatment for rapid relief of 
suicidal ideation is an important and advantageous intervention for suffering patients.  
 
The use of ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has 
garnered extreme interest in the past decade as a rapid-acting antidepressant. More recently, it is 
being investigated to specifically reduce suicidal ideation (SI). First approved in 1970 by the 
U.S. Food and Drug Administration (FDA) for anesthetic use, it shows potential for treatment 
resistant-major depressive disorder (TRD), bipolar depression (BD), post-traumatic stress 
disorder (PTSD), and SI.7 Despite its serious side effects at higher doses and potential for abuse, 
ketamine’s other properties make it a potential agent for short-term therapy.  
 
Ketamine is a drug that is in the early stages of investigation and use for suicidal, hospitalized 
patients who require safe management. Other medical therapies are guided towards long term 
reduction in suicide risk, leaving a gap in the acute management of patients with mood disorders. 
Our objective is to compare the efficacy of IV ketamine versus midazolam to reduce acute 
suicidality.  
 
CASE 
A 47-year-old woman with a history of treatment-resistant depression was admitted to the 
hospital after being found unconscious by her husband at home following a self-poisoning 
attempt using her prescribed bromazepam (1200mg).8 After full resolution of her delirium, she 
reported a history of suicidal plans for approximately 6 months.9  On being questioned, she had 
clear suicidal intent despite adhering to her prescribed risperidone and selegiline, reported that 
she would have preferred to die, and presented with full depressive symptoms including deep 
hopelessness, anhedonia, and feeling unsafe at home. During previous suicidal attempts, the 
patient remained suicidal despite sedation by diazepam and venlafaxine. We offered her the 
option of administering ketamine infusion. Can ketamine be used to treat the patient’s acute SI? 
  
METHODS 
 
A search of PubMed and PsychNET was performed in September 2018 using the terms 
“ketamine,” “suicide,” and “depression” with a filter for human clinical trials and yielded a total 
of 20 non-duplicated articles. Inclusion criteria included randomized control trials published 
within the last 5 years. Individual studies were screened. Those that were excluded did not use 
midazolam as the control or suicidal ideation as the treatment outcome. Others were excluded 
because they were not randomized clinical trials or the treatment was given intranasally instead 
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of IV. One study was removed due to it being a proof of concept study. Three studies were 
appropriate and selected for review. Figure 1 demonstrates the article selection process.  
 
 
 
Figure 1. Flowchart depicting the methods for selecting eligible studies for review 
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RESULTS 
 
Overall study design 
The three articles selected had comparable patient demographics, methodologies, and outcome 
measurements (Table 1). Inclusion and exclusion criteria for the three studies were relatively 
similar. These studies used several rating scales to measure SI; therefore, descriptions of these 
scales can be found in the supplementary material. We compared the findings of clinically 
relevant SI scores and effect sizes between treatment groups.  
 
 
 
Study 1. Grunebaum et al. Ketamine for rapid reduction of suicidal thoughts in major 
depression: a midazolam-controlled randomized control trial.10 
 
Study Objective  
To test the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant 
suicidal ideation in patients with major depressive disorder (MDD). 
  
Study Design 
Participants: 80 adults 18-65 years old with MDD were enrolled in a randomized, blocked 
design, clinical trial. Further population information is shown in Table 2. Patients with a DSM-
IV diagnosis of MDD, defined by a score of > 16 on the 17-item Hamilton Depression Rating 
Scale (HAMD-RS) and a score of > 4 on the Scale for Suicidal Ideation (SSI), were included. 
Exclusion criteria are further described in Table 1.   
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Grunebaum et al. Murrough et al. Price et al.
Study style RCT RCT Two Site double blind RCT
Patient (N) 80 24 57
Midazolam: M = 14, F = 26 Midazolam: M = 4; F = 8 Midazolam: M = 11; F = 10
Ketamine: M = 18, F = 22 Ketamine: M = 4; F = 8 Ketamine: M = 16; F = 20
Midazolam: 40.7 Midazolam: 39.1 Midazolam: 43.8
Ketamine: 38.4 Ketamine: 45.8 Ketamine: 48.6
Ketamine dose (mg/kg) 0.5 0.5 0.5
Midazolam dose (mg/kg) 0.02 0.045 0.045
RCT: randomized control trial; M: male; F: female
Table 2. Study Population Information
Gender
Mean age (years)
 
 
Intervention: Participants were randomly assigned to receive IV racemic ketamine hydrochloride 
at 0.5 mg/kg or midazolam at 0.02 mg/ kg infused over 40 min. Patient response was assessed at 
24 hours (day 1) after infusion. Patients were allowed to stay on their current dosage of 
antidepressant medication. 
 
Outcome measures: Raters were doctoral or master’s level psychologists. The clinician rated SSI 
assessed current severity of suicidal ideation with 19 items scaled from 0 (least severe) to 2 
(most severe). The SSI assessment was administered at screening, baseline within 24 hours 
before infusion, at 230 min after infusion, at 24 hours after infusion (day 1), and at weeks 1-6 of 
follow-up. 
 
Randomization and Blinding: Patients and study personnel were blind to treatment. Patients and 
raters were asked on day 1 whether they thought the infusion was midazolam or ketamine or if 
they had “no idea.” Treatment response was defined as a day 1 SSI score > 50% below baseline. 
 
Statistical Analysis: The study was powered assuming a two-sided test of the group effect at an 
alpha level of 0.05. A sample size of 70, 1:1 each treatment, provided > 80% power to detect a 
25% reduction in SSI score over 24 hours in the ketamine group and no reduction in the 
midazolam group.  
 
Study Results 
Primary Outcome Measure: Day 1 Suicidal Ideation: The average SSI score at day 1 post- 
infusion was lower than baseline in both ketamine and midazolam treatments (14.2 vs 5.8 and 
15.8 vs 11.8, respectively), but the average SSI score at day 1 was 4.96 points lower in the 
ketamine group compared with the midazolam group (95% CI = 2.33-7.59; t = 3.75; df  = 77, p < 
0.001). The comparison in reduction between the two groups yielded a Cohen’s d score of 0.75. 
Baseline borderline personality disorder diagnosis as a covariate had little effect on the results. 
Of note, SSI is considered to have a greater than 90% correlation with the Beck scale for Suicidal 
Ideation (BSI) scoring system. Summaries of results are found in Table 3 and Figure 2. 
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BL Day 1 BL Day 1 BL Day 1 BL Day 1 BL Day 1 BL Day 1
Ketamine 14.2 5.8* 17.5 10.8 3.8 1.8* 6.11 1.13* 1.61 0.72 0.15 -2.23
Midazolam 15.8 11.8 18 14 3.9 3.3 6.19 3.95 1.48 1.24 -0.21 -0.91
SSI: Scale for Suicidal Ideation; BSI: Beck Scale for Suicidal Idation; MADRS-SI: Montgomery-Asberg Depression Rating Scale- Suicidal Ideation; 
SIcomp: summing z-scores on the BSS, MADRS-SI, and Quick Inventory of Depressive Symptomatology-Self Report. *p <0.05
Table 3. Mean SI scores
Murrough et al. Grunebaum et al. 
MADR-SI SIcompMADR-SI BSIBSISSI
Price et al. 
 
 
  
 
Figure 2. Percent reduction of mean SI score at baseline and day 1. 
 
Secondary Outcome Measures: Suicidal ideation: Patients who responded on the SSI at day 1 
were 2.85 times more likely to be treated with ketamine than midazolam. Four patients required 
treatment with ketamine in order to have an SSI response (NNT = 4). While not statistically 
significant, an exploratory analysis showed the odds of an SSI score of 0 at day 1 were 2.8-fold 
greater for the ketamine group. At day 1, SSI worsening was observed in nine midazolam 
patients and two ketamine patients.  
  
Study Critique 
There is no established definition of a clinically meaningful reduction in score on a standard 
suicidal ideation scale. Despite utilizing midazolam as a more accurate control than saline, 
patients were able to correctly guess the blinded drugs in 42% of midazolam and 44% of 
ketamine cases (x2 = 0.02, df = 1, p = 0.895). Patients guessed correctly 55% of the time with 
both drugs (p = 1.000). This is evidence that midazolam is still imperfect as a placebo. A lower 
dose of midazolam compared to other studies was used to reduce additive sedation. Another 
critique of this study is that it used mixed diagnoses, inpatient and outpatient settings, and a 
higher midazolam dose compared to other similar studies. This study used a clinician-reported 
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SSI whereas other previous studies used a self- reported SSI. While self-reported and clinician-
rated versions correlate >0.90, patients tend to report higher scores than clinicians. This study 
also allowed patients to continue their regular antidepressant medication while other studies 
employed a medication washout during the week before the trial began. Additionally, more 
patients treated with ketamine had borderline personality disorder than in the midazolam group 
(28% compared with 8%).  
 
Study 2. Murrough et al. Ketamine for rapid reduction of suicidal ideation: a randomized 
controlled trial.11 
 
Study Objective 
To assess the rapid antidepressant effects of ketamine in reducing suicidality in patients with a 
variety of psychiatric disorders. 
  
Study Design 
Participants: 24 participants, including males and females 18-80 years old, were enrolled in the 
study. Ten subjects were treated as inpatients and 14 as outpatients. Among the patients, there 
was a variety of mental health disorders (54% MDD, 29% BPD, 12.5% PTSD. 62.5% had 
history of suicide attempt). They were enrolled in a single-site randomized control trial from 
2012-2014. Further population information is shown in Table 2. Patients who had clinically 
significant SI on the Montgomery-Asberg Depression Rating Scale (MADRS-SI score > 4; range 
0-6) were included. Patients were excluded if they had a current suicidal intent as indicated by a 
4 or 5 on the Columbia Suicide Severity Scale (CSSS). Other exclusion criteria are described in 
Table 1. Patients were screened during study enrollment, and again the morning of the infusion. 
Written consent was obtained from all participants. 
 
Intervention: Two groups either received 0.5 mg/kg racemic ketamine hydrochloride or 0.045 
mg/kg midazolam over a 40 minute infusion in double-blind conditions. Patients were allowed to 
stay on their current dosage of antidepressant medication. 
 
Outcome measure: Patients’ suicidal intent was measured by the BSI scale at baseline and 24 
hours (day 1). Secondary suicidal intent was measured by the MADRS-SI, Quick Inventory of 
Depressive Symptomatology-Self Report (QIDS-SR), and Concise Associated Symptoms 
Tracking scale scores. Scores were reassessed at 24, 48, 72 hours and again at 7 days post-
infusion. 
 
Randomization: Randomization into two groups was generated by the research pharmacy using 
permuted blocks of size six. All investigators, anesthesiologists, raters and patients were blinded 
to randomization. 
 
Statistical Analysis: The intention-to-treat sample included all participants who were randomized 
and completed at least one post-treatment assessment. SI severity was compared between the two 
groups using separate analysis of covariance (ANCOVA) models, controlling for baseline SI 
levels. Sample size was based primarily on feasibility. Treatment effects are quantified as mean 
differences between groups, and associated effect sizes are based on standardized mean 
difference (Cohen’s d). All statistical tests were two-sided with an alpha set at 0.05.  
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Study Results 
Primary outcome: Day 1 Suicidal Ideation BSI: All participants completed the study, and all 
reported similar side effects of the medications, most commonly headache, dizziness and 
anxiety. At day 1, BSI score changes were reduced in both treatment groups compared to 
baseline; however, the reductions were similar between both the ketamine and midazolam groups 
(10.8 + 8.5, 14.0 + 10.2,), as seen in Table 3. The association between ketamine and midazolam 
groups resulted in a small Cohen’s d score of 0.34. 
 
Secondary Outcome: Day 1 Suicidal Ideation MADRS-SI:  MADRS-SI scores were significantly 
lower in ketamine compared to midazolam (1.8 ± 1.9 and 3.3 ± 1.6, respectively, F1,21 = 4.3, p 
= 0.05, Cohen’s d = 0.86). 
 
Tertiary Outcome: Day 2 Suicidal Ideation: At 48 hours, a difference emerged showing 
improvement in BSI scores in the ketamine group (8.8 + 8.3) compared to midazolam (5.3 + 
10.9;  F1,21 = 1.04, p = 0.32, Cohen’s d = 0.34), but MADRS-SI was no longer significant (1.8 ± 
1.9 and 3.2 ± 1.8, respectively; F1,21 = 3.56, p = 0.077, Cohen’s d = 0.77). After 72 hours, this 
difference was no longer apparent in either metric. The authors performed a linear correlation 
between BSI change and MADRs score and found non-significant positive associations at both 
24 and 48 hours. 
 
Study Critique 
This study explored the effect of ketamine on patients with co-occurring psychiatric disorders 
with the intention of observing efficacy of ketamine across multiple high-risk groups. This is 
advantageous because suicide is often comorbid with multiple mental health disorders; however, 
it weakens the strength of results for each disorder. Data regarding individual patient results was 
not given for the primary and secondary outcome measurements, and there were no baseline 
measurements provided to compare results. Differences were calculated using linear graphs 
rather than quantitative data. This study had a small sample size (n = 24), which may impact 
findings. 
 
Study 3. Price et al. Effects of ketamine on explicit and implicit suicidal cognition: a 
randomized controlled trial in treatment-resistant depression.12 
 
Study Objective 
To evaluate the effects of ketamine as compared to a sedative in reducing suicidality in patients 
with treatment-resistant depression. 
  
Study design 
Participants: 57 patients with TRD were enrolled in a double-blind randomized controlled trial. 
Patients were diagnosed with MDD established by the SCID-I/P interview, and were determined 
to be treatment resistant if they failed at least three trials of antidepressant medication therapies. 
Prior to treatment, patients were assessed for depressive symptoms using the MADRS and 
QIDS-SR. Further inclusion and exclusion criteria are described in Table 1, and further 
population information is shown in Table 2. Patients were free of psychotropic medication for ≥ 
1 week (four weeks for fluoxetine). 
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Intervention: Both groups were admitted overnight, and in the morning, were administered a 
single infusion of either 0.5 mg/kg of ketamine IV or 0.045 mg/kg of midazolam IV over 40 
minutes. Patients remained inpatient the night after the infusion, and suicidal measurements were 
repeated at 24 hours post infusion.  
  
Outcome Measures: Following infusion, all patients completed measures of explicit suicidal 
ideation. Explicit measurements used BSI with the clinician-rated SSI. To reduce Type 1 error 
and preserve power, a composite index score (SIcomposite) was calculated by summing z-scores on 
the BSI, MADRS-SI, QIDS-SR.  
  
Randomization and Blinding: The patients and researchers were blinded, and patients were 
randomly assigned to either the ketamine or midazolam group at a 2:1 ratio, resulting in 36 
ketamine treatments and 21 midazolam treatments. Midazolam was used as placebo rather than 
saline in order to blind patients and providers to the sedative effects of ketamine by comparing it 
to a benzodiazepine. 
  
Statistical Analysis: 24 hour scores were compared across groups using ANCOVA with baseline 
values as a covariate. A two-tailed P value was used for all analyses. Statistical trends at two-
tailed P < 0.1 are reported along with significant effects (P < 0.05).  
  
Study Results 
Primary Outcomes:  Day 1 Suicidal ideation: The SIcomposite was reduced in both treatment 
groups. SIcomposite scores and isolated BSI scores are shown in Table 3. The comparison in 
composite scores between ketamine and midazolam groups showed a Cohen’s d score of 0.82.  
 
Secondary Outcomes: Suicidal Ideation, Explicit and Implicit Measurements: BSI and MADRS-
SI scores were reduced in both groups as seen in Table 3. The BSI scores from baseline to day 1 
were significantly reduced in the ketamine group compared to the midazolam group (6.11 to 
1.13, and 6.19 to 3.95, respectively; p = 0.04). MADRS-SI scores from baseline to day 1 showed 
a greater reduction in the ketamine group than the midazolam group (1.61 to 0.72 and 1.48 to 
1.24, respectively; Cohen’s d = 0.86). 
 
Study Critique 
Strengths of this study include the use of multiple explicit and implicit measurements of 
suicidality, and this study is the only one that evaluated implicit measurements. This is an 
important distinction because suicidal intent is often difficult to understand, and this study 
highlighted the differences in implicit and explicit measurements. A weakness of this study is the 
inability to measure patients that are imminently suicidal. The effect of studying suicidality in 
patients that are suicidal inclined versus suicide imminent has a major implication in the true 
effectiveness of the medication. Another weakness is the limited follow-up of only measuring at 
24 hours post-infusion. The published paper itself did not specifically mention inclusion or 
exclusion criteria, although it appears to use the same criteria as Murrough et al. 
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DISCUSSION 
 
Overall, patients treated with IV ketamine exhibited rapid, clinically relevant reductions in SI, 
which were significantly greater than reductions observed in midazolam-treated patients. For 
Gruenbaugh et al., the average SSI score at day 1 post-infusion was lower than baseline using 
both treatments, but the average score was significantly lower in ketamine-treated patients than 
midazolam-treated patients (p < 0.001, Cohen’s d = 0.75). In Murrough et al., BSI scores were 
similarly reduced for ketamine and midazolam-treated patients while MADRS-SI scores were 
significantly lower for ketamine-treated patients (p = 0.5, Cohen’s d = 0.86). For Price et al., the 
BSI score was significantly reduced in ketamine-treated patients compared to midazolam (p = 
0.04). Ketamine-treated patients showed a large effect size difference compared to midazolam 
when measured on the MADRS-SI and SIcomposite scores in Price et al. (Cohen’s d = 0.86 and 
0.82, respectively). No studies showed a significant SI reduction when treated with midazolam. 
These studies showed that using most scales, ketamine significantly reduced suicidal ideation 
with moderate to large effect sizes. Ketamine can be used to treat acute suicidal ideation in 
patients with MDD or TRD, but more research is needed to make similar conclusions in patients 
with other co-occurring psychiatric disorders. 
 
Despite there being no established definition of a clinically meaningful reduction in score on a 
suicidal ideation scale, studies suggest that patients who reported 50% reduction in SI symptoms 
at 24 hours had one-third the risk of later self-harm events over 24 days, compared with those 
whose SI remained over 50%.13 The United Kingdom's National Institute for Health and Care 
Excellence considered a Cohen’s d value ≥ 0.5 to be clinically significant. Therefore, the three 
reviewed studies suggest that the reduction in SI at day 1 after ketamine infusion is clinically 
meaningful (Figure 2). Of note, Murrough et al. observed conflicting results between two 
different suicidal ideation scales at day 1: SI measured using the BSI was reduced in both the 
treatment and placebo trial, but not significantly. However, the MADRS-SI score was 
significantly lower in patients treated with ketamine compared to midazolam. Despite this, when 
taken together, these studies add to the body of evidence that ketamine can reduce suicidal 
ideation in patients suffering from an acute suicidal episode. 
 
The studies have several limitations. First, each of the three studies evaluated suicidal ideation 
slightly differently, but the Beck Scale for Suicidal Ideation was incorporated into all three 
results. Grunebaum et al. used the SSI, which has greater than 90% correlation with BSI. 
Murrough et al. was the only researcher who used the BSI as the primary outcome, but Price et 
al. used BSI as part of a composite score. There is no universally accepted suicidal ideation 
scale, but BSI (or a strongly correlated scale) was used in all three studies and makes for a useful 
comparison in all three studies. Secondary measurements for Murrough et al. and Price et al. 
both included the MADRS-SI scale as well. Future studies should attempt coherence in patient 
recruitment and rating scales. 
 
A second limitation is the differences in the criteria for patient inclusion. Murrough et al.’s 
research targeted patients across a range of mood and anxiety disorders including MDD, bipolar 
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disorder, PTSD, borderline personality disorder, social anxiety disorder, obsessive compulsive 
disorder, and others. Price et al. enrolled only suicidal patients with treatment-resistant 
depression. Grunebaum et al. enrolled suicidal patients with major depressive disorder, but some 
patients also had diagnoses of borderline personality disorder. The array of psychiatric disorders 
Murrough et al. included may have contributed to the differing results. However, a diverse 
patient population is important to include due to the multifactorial sources of SI. 
 
There was already strong evidence that subanesthetic ketamine administered to patients with 
MDD and/or suicidal ideation have rapid-acting anti-suicidal effects when compared with a 
placebo.14–16 However, a limitation of these initial studies is the lack of an ideal control. When 
using saline as a placebo, patients have the possibility to become unblinded from their study 
group given the psychoactive properties of ketamine compared to saline. The studies we 
reviewed use midazolam as the control because its sedative effects make it more difficult for 
patients to discern which type of therapy they receive, thus further strengthening the evidence 
that ketamine is efficacious in reliving suicidal ideation.17 Ongoing studies of ketamine currently 
use a psychoactive control based on these findings. Despite midazolam being an improved 
control, limitations still exist. Grunebaum et al. noted that raters correctly guessed the drug they 
were administered in 42% of midazolam and 44% of ketamine cases (p = 0.895), while the other 
authors make no mention of blinding results after administration. 
 
The research discussed may be affected by several biases. Researches on Grunebaum et al. have 
royalties for use of the Columbia Suicide Severity Rating scale and have stock in Bristol-Myers 
Squibb. Dr. Murrough et al. serves on boards for Janssen Research and Development and 
Genentech, is a consultant for clinical research and other pharmaceutical companies, has patents 
pending for ketamine use in mood and anxiety disorders and SI. Other authors of Murrough et al. 
and Price et al. have received consulting fees from pharmaceutical companies, academic 
institutions, biotech firms, and others. They also have licensing agreements for the use of 
ketamine as therapy for TRD, and have patents pending for ketamine treatment for PTSD, among 
others. Many authors may benefit financially if ketamine gains approval for the treatment of 
various psychiatric disorders.  
 
Overall, the conclusions of these studies indicate that (1) ketamine is a promising therapy for 
acute SI treatment, and (2) the NMDA receptor is one of the pathological mechanisms implicated 
in suicidal ideation. These findings open the door to further development of treatments for 
suicidality that target similar mechanisms of action. Extensive research into the NMDA receptor 
shows that glutaminergic neurotransmission and NMDA dysregulation contribute to the 
pathology of MDD, a disorder that puts patients at significant risk for suicide.18–20 It is uncertain 
whether suicidal ideation and depressive symptoms are of two separate mechanisms, but the 
results of the studies reviewed here indicate that the NMDA receptor is one of the pathological 
mechanisms implicated in suicidal ideation. In conclusion, ketamine can be used to reduce 
suicidal ideation.  
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PATIENT APPLICATION 
 
Two of the three studies produced clinically relevant reductions in SI within one day, and a third 
study reduced SI within 48 hours. If the patient received ketamine, 0.5 mg/kg IV over 40 
minutes, her acute SI can be relived in one day. Rather than ketamine, she may have been 
admitted to a psychiatric unit and treated with electroconvulsive therapy, both of which are 
expensive and stigmatizing. She can be managed and transferred to other units if her other 
conditions require management. Also, her medications can be reassessed and managed with less 
risk of immediate suicide. We recommend ketamine as treatment for acute SI.  
 
 
CONCLUSION 
 
Infusion of ketamine reduces suicidal ideation in patients with depression. Suicide is still a 
poorly understood process, and further investigation into its etiology could potentially yield more 
advantageous treatment interventions. However, with evidence of NMDA receptor’s 
involvement in MDD, further research into ketamine-like drugs should be pursued. Future 
studies should also attempt to expand the therapeutic capabilities of ketamine as an anti-suicidal 
drug, particularly in patients that are actively suicidal. In addition to acute SI, ketamine shows 
promise in long-term reduction of symptoms for patients with MDD, PTSD, bipolar disorder, 
and other mood disorders.16,21–23 Some research is being conducted into intranasal administration 
of ketamine, which would allow for more attainable outpatient therapy.24 The benefits of 
ketamine are significant because by reducing suicidal ideations, lives can be saved. Ketamine as 
anti-suicidal drug can be risky because its advantageous short-term effects could potentially be 
misinterpreted as long-term effects as well. Ketamine is best used as a short-term therapy to 
reduce suicidal ideations until a more effective anti-depressive drug regimen can be initiated.  
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SUPPLEMENTARY MATERIAL 
 
Beck Scale for Suicidal Ideation (BSI) 
 Goal: Assess suicidal ideation 
 Scoring: 21 item 
 Interpretation: High scores indicate more severe suicidality 
 
Columbia Suicide Severity Scale 
 Goal: Measure suicidal ideation and intensity of ideation 
 Scoring: 38 item checklist 
 Interpretation: higher scores indicate more severe suicidality 
 
Hamilton Depression Rating Scale (HAMD-RS) 
 Goal: measure a patient’s level of depression 
 Scoring: 21 items, first 17 are scored either 0-4 or 0-2 
 Interpretation: >7 indicates depression  
 
Montgomery-Asberg Depression Rating Scale (MADRS-SI) 
 Goal: Diagnosing depression 
 Scoring: 10 item, scored 0-6 
 Interpretation: > 4 considered significant suicidality 
 
Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) 
 Goal: Measure depression symptoms 
 Scoring: 16 item, with a single suicidality item scored 0-3 
 Interpreation: High scores indicate more severe depression 
 
SCID-I/P interview 
 Goal: Establish diagnosis of major depressive disorder 
 Scoring: Clinical Interview 
 Interpretation: Per interviewer 
 
Scale for Suicidal Ideation (SSI) 
 Goal: quantify and assess current suicidal ideation 
 Scoring: 19 item, scored 0-2 
 Interpretation: Higher scores indicate more severe suicidal ideation 
 
 
 
 
